Journal: Journal of Functional Biomaterials

Article Title: Cytocompatibility Assessment of L-PBF-Manufactured Zinc–Silver–Copper Alloys for Customized Biodegradable Medical Implants

doi: 10.3390/jfb17030146

Figure Lengend Snippet: ( A ) Representative images of the direct cytocompatibility contact test with SAOS-2 cells are presented. The top row ( a ) shows the tested sample plates (black) at the top of the image, with cells growing in direct contact on the bottom of the six-well plate (five times magnification). ( b ) The cell density at a 12 mm distance from the test plates (ten times magnification). ( B , D ) Three different extract concentrations (undiluted, diluted 1:3 and diluted 1:10) from the three L-PBF-manufactured Zn alloys (ZnAgCu, ZnAgCuMn, and ZnAgCuTi), rolled Zn, Cu, and Ti controls were tested, and the proliferation of L929 ( B ) and SAOS-2 ( D ) cells was determined after 24 h. ( C , E ) Live/dead staining of L929 ( C ) and SAOS-2 ( E ) cells growing directly on top of the samples is shown. Red and yellow staining indicate dead or dying cells, respectively, while living cells appear green. Each test was carried out four times with four replicates per sample. Shown are the mean values with their corresponding standard deviations. All results were normalized to control cells grown in cell culture medium without extract (proliferation equals 100%). To calculate statistical significance, a one-way ANOVA followed by a Tukey test was carried out (** p < 0.01 and **** p < 0.0001).

Article Snippet: In addition, the human primary osteogenic sarcoma cell line SAOS-2 (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH), cultured in McCoy’s 5A medium (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) supplemented with 15% FBS (Bio&SELL GmbH) and 1% L-glutamine (Thermo Fisher Scientific Inc.), was used.

Techniques: Staining, Control, Cell Culture

Journal: Journal of Functional Biomaterials

Article Title: Cytocompatibility Assessment of L-PBF-Manufactured Zinc–Silver–Copper Alloys for Customized Biodegradable Medical Implants

doi: 10.3390/jfb17030146

Figure Lengend Snippet: Time dependency of ion release and cytocompatibility of undiluted extracts tested for 24 h with SAOS-2 cells from untreated ( A ) and polished ( B ) L-PBF-manufactured plates. Extracts collected daily over a period of 10 days. ( C ) OM of untreated and polished plates before and after 10 days of immersion. The mean proliferation values with the corresponding standard deviation of independent experiments ( n = 4) are plotted graphically. All results were normalized to the control cells grown in cell culture medium without extract (=100%). Significance was determined using one-way ANOVA followed by a Tukey test (* p < 0.05; ** p < 0.01; *** p < 0.001; and **** p < 0.0001). ( D , E ) ICP-OES ion concentration measurement. ( D ) Zn 2+ release of the different alloys into daily renewed McCoy’s medium from day 1 to day 10. The extracts were taken from untreated and freshly polished samples. The mean values with the corresponding standard deviations of five independent experiments are plotted. ( E ) Ion concentrations of Zn 2+ , Ag + , Cu 2+ , and Mn 2+ release of ZnAgCuMn into the daily changed McCoy’s medium ( n = 5).

Article Snippet: In addition, the human primary osteogenic sarcoma cell line SAOS-2 (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH), cultured in McCoy’s 5A medium (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) supplemented with 15% FBS (Bio&SELL GmbH) and 1% L-glutamine (Thermo Fisher Scientific Inc.), was used.

Techniques: Standard Deviation, Control, Cell Culture, Concentration Assay

Journal: Journal of Functional Biomaterials

Article Title: Cytocompatibility Assessment of L-PBF-Manufactured Zinc–Silver–Copper Alloys for Customized Biodegradable Medical Implants

doi: 10.3390/jfb17030146

Figure Lengend Snippet: Cytocompatibility extract test with SAOS-2 cells cultivated for 24 h in extracts from untreated, new polished and aged polished samples. The mean proliferation values with the corresponding standard deviation of independent experiments ( n = 8) are plotted graphically. All results were normalized to the control cells grown in cell culture medium without extract (=100%). Significance was determined using one-way ANOVA followed by a Tukey test (* p < 0.05; ** p < 0.01).

Article Snippet: In addition, the human primary osteogenic sarcoma cell line SAOS-2 (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures GmbH), cultured in McCoy’s 5A medium (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) supplemented with 15% FBS (Bio&SELL GmbH) and 1% L-glutamine (Thermo Fisher Scientific Inc.), was used.

Techniques: Standard Deviation, Control, Cell Culture

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Anti-myeloma activity of the CXCR4 antagonist WZ811

doi: 10.1007/s00109-026-02650-4

Figure Lengend Snippet: CXCR4 expression levels in MM. A The expression of CXCR4 at the protein level was analyzed in a panel of 14 MM cell lines (MM.1S, OPM-1, OPM-2, RPMI-S, RPMI-DOX6, RPMI-DOX40, RPMI-LR5, RPMI-MR20, JJN-3, KMS-11, L-363, OCI-My5, OCI-My7, and U266) by flow cytometry (FACS Canto II flow cytometer, Becton Dickinson), represented by histograms of CXCR4-BV421 positive expression (blue) compared to the negative Ig isotype control (grey), and B by western immunoblot analysis using anti-CXCR4 and anti-GAPDH (used as a loading control) antibodies. The fold change of the geometric mean of CXCR4 expression relative to the isotype fluorescent control is shown. The data are representative from three independent experiments. C CXCR4 expression at the transcriptional mRNA level was examined using RT-PCR, showing mRNA levels of CXCR4 in MM cell lines. The data are from three independent experiments and are presented as means ± standard deviation. D The representative 3D flow cytometry-based histograms depict CXCR4 expression on plasma cells (PC) in healthy donors (HD; black), monoclonal gammopathy of unknown significance (MGUS; light blue), smoldering MM (SMM; grey), newly diagnosed MM (NDMM; brown), and relapsed/refractory MM (RRMM; blue), compared to negative Ig isotype control (NEG; pink). The column bar graph shows the percentage of CXCR4 expression on normal PC (expressing CD138+/CD45+/CD38+) and non-PC of healthy donors (HD; n = 10), and malignant PC (expressing CD138+/CD45low/CD38++) and non-PC from primary bone marrow-derived cells of premalignant MGUS ( n = 15) and SMM ( n = 23), as well as active NDMM ( n = 39) and RMM ( n = 102) MM patients analyzed by flow cytometry and calculated using the Mann-Whitney U test, * p < 0.05 and **** p < 0.0001

Article Snippet: MM cell lines MM.1S (RRID:CVCL_8792) and U266 (RRID:CVCL_0566) were sourced from the American Type Culture Collection (ATCC, Manassas, VA), while OPM-2 (RRID:CVCL_1625) and L-363 (RRID:CVCL_1357) cell lines were acquired from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany).

Techniques: Expressing, Flow Cytometry, Control, Western Blot, Reverse Transcription Polymerase Chain Reaction, Standard Deviation, Clinical Proteomics, Derivative Assay, MANN-WHITNEY

Journal: Journal of Molecular Medicine (Berlin, Germany)

Article Title: Anti-myeloma activity of the CXCR4 antagonist WZ811

doi: 10.1007/s00109-026-02650-4

Figure Lengend Snippet: WZ811 decreases survival of MM cells. A MM cell lines (MM.1S, OPM-1, OPM-2, RPMI-S, RPMI-DOX6, RPMI-DOX40, RPMI-LR5, RPMI-MR20, JJN-3, KMS-11, L-363, OCI-My5, OCI-My7, and U266 cells) were exposed to indicated concentrations (0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h and 72 h. The cell survival was determined by MTT assay, and the EC 50 values of WZ811 were examined in MM cell lines for 48 h and 72 h using the CalcuSyn software. B Freshly sorted malignant bone marrow PC (expressing CD138+/CD45low/CD38++; n = 14) and tumor microenvironment cells (non-PCs; n = 14), both obtained from the same primary MM patient samples, were exposed to the indicated concentrations (1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h. The cell survival was assessed by CellTiterGlo assay, and the EC 50 values of WZ811 in both PC and non-PC populations were determined for 48 h using the CalcuSyn software. If an exceptionally high EC 50 value was observed, it was reported as “n.a.” C Freshly isolated peripheral blood mononuclear cells (MNCs) from healthy donors (HD; n = 6) were exposed to indicated concentrations (0.625, 1.25, 2.5, 5, 10, 20, and 40 μM) of WZ811 for 48 h, and cell survival was assessed by MTT assay. The EC 50 values of WZ811 were determined in HD for 48 h using the CalcuSyn software. EC50 data are not presented due to exceptionally high values. Each treatment with a specific concentration of WZ811 was performed in triplicate. The presented data are mean ± standard deviation, expressed as survival/viability relative to untreated controls. EC 50 (half maximal effective concentration) is shown with lower and upper 95% confidence intervals (CI). D The median EC 50 values of WZ811 in MM cell lines, malignant PC, and non-PC of primary cells derived from MM patients, as well as MNCs of HD, were compared and calculated using One-way ANOVA on ranks followed by Kruskal-Wallis multiple comparison test, with *** p < 0.001

Article Snippet: MM cell lines MM.1S (RRID:CVCL_8792) and U266 (RRID:CVCL_0566) were sourced from the American Type Culture Collection (ATCC, Manassas, VA), while OPM-2 (RRID:CVCL_1625) and L-363 (RRID:CVCL_1357) cell lines were acquired from the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ, Braunschweig, Germany).

Techniques: MTT Assay, Software, Expressing, Isolation, Concentration Assay, Standard Deviation, Derivative Assay, Comparison